Merck and Pfizer are leading investment options in the pharmaceutical healthcare sector given the lower risk and higher return they offer investors over smaller capitalization stocks. Third quarter earnings for Merck and Pfizer showed significant potential for value gains as both drug manufacturers beat earnings expectations and increased their guidance for 2015 as a result of improving dynamics in the healthcare sector.